Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LNP 3794

Drug Profile

LNP 3794

Alternative Names: LNP-3794

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lupin
  • Class Antineoplastics
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 29 Sep 2019 Lupin terminates phase II/III trial in Non-small cell lung cancer (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) in India, before September 2019 (CTRI/2017/12/010781)
  • 25 Sep 2019 Lupin terminates a phase II trial in Non-small cell lung cancer (Monotherapy, Late stage disease, Metastatic disease, Second-line therapy or greater) in India (CTRI/2019/01/017245)
  • 04 Sep 2019 Boehringer Ingelheim in-licenses LNP 3794 from Lupin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top